Researcher Yoshida from Safety BU to Present a Poster at the 10th Annual Meeting of the Japan Nucleic Acid Therapeutics Society

2025.06.20

Our researcher, Ikuma Yoshida from the Safety Business Unit, will present a poster at the 10th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan, taking place from July 1 to 3, 2025 (JST) at the Kobe International Exhibition Hall. If you’re attending the conference, we warmly encourage you to stop by and view the poster.

Conference Name: the 10th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan

Date & Time: Wednesday, July 2nd, 17:20 – 18:20  (JST)

Location: Kobe International Exhibition Hall

Title: Development of an Exploratory Renal Toxicity Prediction Method for Oligonucleotide Therapeutics Using Human Proximal Tubule Epithelial Cells

Poster No.: P2-094

Presenter: Ikuma Yoshida Safety Business Unit

Presentation Summary
Renal toxicity is one of the most common reasons for discontinuation of oligonucleotide therapeutics, particularly antisense oligonucleotides (ASOs). Induction of renal toxicity typically requires long-term repeated dosing, whereas hepatotoxicity is often caused by short-term exposure. The conventional predictive method using human primary renal proximal tubule epithelial cells (RPTECs) with the free uptake approach has limitations for screening due to the large amount of test compounds required and the lengthy 9-day testing period.
We have developed a novel method for detecting ASO-induced renal toxicity using RPTECs with transfection reagents. This approach can reduce the testing period by 77% and the ASO requirements by 99.9% compared to the conventional free-uptake method. In addition, the predictive accuracy was 92% (12/13). We believe this technology will be useful for the early selection of oligonucleotides with lower risk of nephrotoxicity in oligonucleotide drug development.

Axcelead DDP’s Soulution
Axcelead DDP provides comprehensive toxicological evaluation services for all stages of oligonucleotide therapeutics development. For in vitro evaluations, we assist in optimizing oligonucleotide candidates using a wide range of systems—from high-throughput screening to detailed toxicity profiling. For in vivo evaluations, we design and conduct animal and pharmacokinetic studies tailored to the specific characteristics of oligonucleotide modalities, and we also support regulatory submissions. We support all challenges related to safety evaluation of nucleic acid therapeutics with our extensive experiences and expertise. Please feel free to contact us if you need assistance.

Related Service: Oligonucleotide